Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).

Trial Details

NCT ID
NCT03533816
Phase
PHASE1
Sponsor
University of Kansas Medical Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • EAGD T-cell infusion (Phase I)
  • EAGD T-cell infusion (Expansion)
Locations (sample)
  • Westwood, Kansas, United States|39.04056,-94.6169
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • The following criteria are used to enroll patients in the study before transplant.
  • Patients with neoplastic hematological disorders with indication of allogeneic transplant according to the National Comprehensive Cancer Network (N…
  • Acute myeloid leukemia \[AML\] in morphologic complete remission with intermediate/high-risk features (per NCCN criteria) or relapsed disease
  • Chronic myeloid leukemia \[CML\] in any chronic phase.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →